These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 31722862)

  • 21. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.
    Barth RE; Aitken SC; Tempelman H; Geelen SP; van Bussel EM; Hoepelman AI; Schuurman R; Wensing AM
    Antivir Ther; 2012; 17(2):377-86. PubMed ID: 22297391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Low-level Viremia on Treatment Outcomes During ART - Is it Time to Revise the Definition of Virological Failure?
    Poveda E; Crespo M
    AIDS Rev; 2018; 20(1):71-72. PubMed ID: 29628513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of targeted viral load testing in diagnosing virological failure in children on antiretroviral therapy with immunological failure.
    Davies MA; Boulle A; Technau K; Eley B; Moultrie H; Rabie H; Garone D; Giddy J; Wood R; Egger M; Keiser O;
    Trop Med Int Health; 2012 Nov; 17(11):1386-90. PubMed ID: 22974345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-Level Viremia Predicts Virological Failure in HIV-Infected Omani Patients Receiving Antiretroviral Therapy.
    Gaifer Z; Boulassel MR
    J Int Assoc Provid AIDS Care; 2020; 19():2325958220979817. PubMed ID: 33372823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV virological non-suppression and its associated factors in children on antiretroviral therapy at a major treatment centre in Southern Ghana: a cross-sectional study.
    Afrane AKA; Goka BQ; Renner L; Yawson AE; Alhassan Y; Owiafe SN; Agyeman S; Sagoe KWC; Kwara A
    BMC Infect Dis; 2021 Aug; 21(1):731. PubMed ID: 34340689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy.
    Aleman S; Söderbärg K; Visco-Comandini U; Sitbon G; Sönnerborg A
    AIDS; 2002 May; 16(7):1039-44. PubMed ID: 11953470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transient viral load increases in HIV-infected children in the U.K. and Ireland: what do they mean?
    Lee KJ; Shingadia D; Pillay D; Walker AS; Riordan A; Menson E; Duong T; Tudor-Williams G; Gibb DM;
    Antivir Ther; 2007; 12(6):949-56. PubMed ID: 17926649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml.
    Easterbrook PJ; Ives N; Waters A; Mullen J; O'Shea S; Peters B; Gazzard BG
    AIDS; 2002 Jul; 16(11):1521-7. PubMed ID: 12131190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Term Immunological and Virological Outcomes in Children Receiving Highly Active Antiretroviral Therapy at Hawassa University College of Medicine and Health Sciences, Southern Ethiopia.
    Fenta DA; Wube TB; Nuru MM
    J Immunol Res; 2021; 2021():2498025. PubMed ID: 33928167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes after viral load rebound on first-line antiretroviraltreatment in children with HIV in the UK and Ireland: an observational cohort study.
    Childs T; Shingadia D; Goodall R; Doerholt K; Lyall H; Duong T; Judd A; Gibb DM; Collins IJ;
    Lancet HIV; 2015 Apr; 2(4):e151-8. PubMed ID: 26413561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa.
    Fox MP; Berhanu R; Steegen K; Firnhaber C; Ive P; Spencer D; Mashamaite S; Sheik S; Jonker I; Howell P; Long L; Evans D
    Trop Med Int Health; 2016 Sep; 21(9):1131-7. PubMed ID: 27383454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy.
    Machado ES; Lambert JS; Watson DC; Afonso AO; da Cunha SM; Nogueira SA; Caride E; Oliveira RH; Sill AM; DeVico A; Tanuri A
    J Clin Virol; 2004 May; 30(1):24-31. PubMed ID: 15072750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Viral load predicts new world health organization stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy, independent of CD4 T lymphocyte value.
    Oliveira R; Krauss M; Essama-Bibi S; Hofer C; Robert Harris D; Tiraboschi A; de Souza R; Marques H; Succi R; Abreu T; Della Negra M; Hazra R; Mofenson LM; Siberry GK;
    Clin Infect Dis; 2010 Dec; 51(11):1325-33. PubMed ID: 21039218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.
    Frange P; Briand N; Avettand-fenoel V; Veber F; Moshous D; Mahlaoui N; Rouzioux C; Blanche S; Chaix ML
    Pediatr Infect Dis J; 2011 Aug; 30(8):684-8. PubMed ID: 21427626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence and determinants of virological failure in HIV-infected children on antiretroviral therapy in rural Cameroon: a cross-sectional study.
    Zoufaly A; Fillekes Q; Hammerl R; Nassimi N; Jochum J; Drexler JF; Awasom CN; Sunjoh F; Burchard GD; Burger DM; van Lunzen J; Feldt T
    Antivir Ther; 2013; 18(5):681-90. PubMed ID: 23502762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
    García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
    AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
    Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
    Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Second-line antiretroviral therapy failure and characterization of HIV-1 drug resistance patterns in children in Mali.
    Sylla M; Dolo O; Maiga AI; Traore FT; Coulibaly YA; Togo J; Fofana DB; Dicko-Traore F; Doumbia S; Orsega S; Diallo S; Murphy RL; Calvez V; Marcelin AG
    Arch Pediatr; 2019 Jul; 26(5):254-258. PubMed ID: 31307909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genotype-Informed Versus Empiric Management Of VirEmia (GIVE MOVE): study protocol of an open-label randomised clinical trial in children and adolescents living with HIV in Lesotho and Tanzania.
    Brown JA; Ringera I; Luoga E; Cheleboi M; Kimera N; Muhairwe J; Kayembe BP; Molapo Hlasoa M; Kabundi L; Yav CWD; Mothobi B; Thahane L; Amstutz A; Bachmann N; Mollel GJ; Bresser M; Glass TR; Paris DH; Klimkait T; Weisser M; Labhardt ND
    BMC Infect Dis; 2020 Oct; 20(1):773. PubMed ID: 33076866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brief Report: Lopinavir Hair Concentrations Are the Strongest Predictor of Viremia in HIV-Infected Asian Children and Adolescents on Second-Line Antiretroviral Therapy.
    Pintye J; Bacchetti P; Teeraananchai S; Kerr S; Prasitsuebsai W; Singtoroj T; Kuncze K; Louie A; Koss CA; Jin C; Phung N; Horng H; Sohn AH; Gandhi M
    J Acquir Immune Defic Syndr; 2017 Dec; 76(4):367-371. PubMed ID: 28825944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.